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Abstract
Introduction: Mechanisms driving the invasiveness of follicular thyroid cancer (FTC) are not fully understood. In our study, we under-
took an unsupervised analysis of the set of follicular thyroid tumours (adenomas (FTA) and carcinomas) to verify whether the malignant 
phenotype influences major sources of variability in our dataset.
Material and methods: The core set of samples consisted of 52 tumours (27 FTC, 25 FTA). Total RNA was analysed by oligonucleotide 
microarray (HG-U133 Plus 2.0). Principal Component Analysis (PCA) was applied as a main method of unsupervised analysis. 
Results: An analysis of biological character of genes correlated to the first six PCs was performed. When genes correlated to the first PC 
were used to cluster FTC and FTA, they appeared in two branches; one, relatively enriched in adenomas, with homogenous expression 
of subset of genes, and the other containing mainly carcinomas, with down-regulation of these genes and heterogeneous up-regulation 
in a smaller cluster of transcripts. Genes highly up-regulated in adenomas included some thyroid-specific transcripts. The second cluster 
of genes, up-regulated in carcinomas, contained mainly immunity-related transcripts. Immune response genes were found in the first, 
third and sixth principal components, improving the discrimination between carcinomas and adenomas.
Conclusions: Our unsupervised analysis indicates that invasiveness of follicular tumours might be considered as the major source of vari-
ability in transcriptome analysis. However, the distance between both groups is small and the clusters are overlapping, thus, unsupervised 
analysis is not sufficient to properly classify them. (Endokrynol Pol 2013; 64 (5): 328–334)
Key words: follicular thyroid carcinoma, follicular adenoma, gene expression
Streszczenie
Wstęp: Rak pęcherzykowy tarczycy (FTC) jest nowotworem którego podłoże molekularne jest mało zbadane. W podjętej analizie trans-
kryptomu oceniono możliwość dyskryminacji raka i gruczolaka pęcherzykowego tarczycy (FTA) na podstawie badań profilu ekspresji 
genów metodą tzw. nienadzorowaną (tzn. na podstawie dominujących źródeł zmienności). Analizę tę prowadzono by sprawdzić czy 
złośliwość guza jest rzeczywiście czynnikiem dominującym dla profilu ekspresji genów w nowotworach pęcherzykowych.
Materiał i metody: Podstawowy zbiór guzów pęcherzykowych obejmował 52 próbki (27 FTC i 25 FTA), z których wyizolowano całkowity 
RNA i poddano badaniu na mikromacierzach HG-U133 Plus 2.0. Otrzymany zbiór normalizowano za pomocą RMA i GC-RMA. Identy-
fikacji głównych źródeł zmienności dokonano metodą analizy głównych składowych (PCA). 
Wyniki: Analizę funkcji biologicznej genów przeprowadzono dla pierwszych 6 składowych głównych. Geny skorelowane z pierwszą 
składową pozwalały wyodrębnić 2 klastry próbek: jeden złożony głównie z gruczolaków, z wysoką ekspresją między innymi transkryptów 
tarczycowo-swoistych, drugi zaś, zawierający większość raków, wykazywał zwiększoną, ale heterogenną ekspresję genów związanych 
z odpowiedzią immunologiczną, a obniżoną ekspresję genów tarczycowych. Geny odpowiedzi immunologicznej stwierdzono wśród 
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transkryptów skorelowanych przebiegiem pierwszej, trzeciej i szóstej głównej składowej; w istotny sposób wpływały one na rozróżnienie 
między FTC i FTA.
Wnioski: W analizie nienadzorowanej stwierdzono, że złośliwość (inwazyjność) nowotworu pęcherzykowego może być jednym 
z głównych źródeł zmienności w transkryptomie tych guzów. Jednak, genomiczna odległość między grupami FTC i FTA jest niewielka, 
a wyodrębnione w analizie nienadzorowanej klastry nakładają się, stąd sama analiza nienadzorowana nie jest wystarczającym narzędziem 
do celów klasyfikacji tych guzów.(Endokrynol Pol 2013; 64 (5): 329–334)
Słowa kluczowe: rak pęcherzykowy tarczycy, gruczolak pęcherzykowy, ekspresja genów
This work was supported by the Ministry of Science and Higher Education grants nr N N401 072637, N N403 194340 and Foundation 
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Introduction
Follicular thyroid cancer is a malignant tumour believed 
to arise from follicular cells in the thyroid gland. Being 
relatively rare compared to the papillary histotype of 
thyroid carcinoma, follicular cancer has not yet been 
thoroughly investigated in regard to the molecular 
mechanisms driving the malignant potential [1–4]. 
It is of special interest, because follicular thyroid 
carcinoma has a benign counterpart - follicular thyroid 
adenoma. What is relatively unique, although resulting 
from the high degree of differentiation in this type of 
cancer and occurring also in other endocrine malignan-
cies, is that there are no cell-specific criteria differentiat-
ing the areas with malignant potential from the fully 
benign tumours [5, 6]. The only defining feature is the 
presence of invasion of tumour capsule and vessels, if 
it is prominent enough to be spotted by a pathologist 
[7, 8]. The degree of invasion defines the subtypes 
of disease (minimally invasive, classical, and widely 
invasive) and certainly influences the reliability of the 
assessment by a pathologist. It is possible that some 
thyroid adenomas are in fact follicular carcinomas with 
no invasion revealed by pathology examination [4]. 
The difficulties described above give rise to the 
question whether the ability of follicular cells to invade 
is an inherent part of their genomic programme. If so, 
detection of that profile in cells could lead to genomic 
tests which on the basis of gene expression (and possibly 
in future also gene mutations and other aberrations) 
provide the information whether the tumour is benign 
or malignant not relying on the presence or absence of 
apparent invasion areas [9]. Unfortunately, comparisons 
on the global scale, i.e. between the full transcriptomes, 
almost always provides certain differences and their 
validation requires large independent samples [4, 9]. 
However, when the genomic distance between groups 
is large, the positive validation in further prospective 
studies is much easier and often leads to clinically sig-
nificant conclusions. 
One method to verify genomic distance between 
classes of samples is so called unsupervised analysis. 
In our bioinformatic study, we discriminate specimens 
on the basis of differences which are the major source 
of variability in the analysed dataset and are evident 
without previous assumptions regarding the sample 
class membership. In our study, we undertake an unsu-
pervised analysis of a set of follicular thyroid tumours 
(both adenomas and carcinomas) to verify whether 
tumour malignancy is the factor influencing major 
sources of variability in our dataset.
Material and methods
We analysed a dataset consisting of 82 samples, 
among them thyroid carcinomas (FTC), thyroid ad-
enomas (FTA) and grossly normal thyroid tissue (N) 
from the lobe of thyroid opposite to the tumours. 
Samples were fresh-frozen collected after surgery 
in the following Polish and German centres: MSC 
Memorial Cancer Centre and Institute of Oncology 
in Gliwice, University of Leipzig, University of Halle, 
and Mainz University Hospital. The study was ap-
proved by the local ethics committees and informed 
consent was obtained from all patients. The core set 
of samples (after exclusion of technical outliers in 
genomic study) consisted of 52 tumours (27 FTC, 25 
FTA), of which 23% were collected from men. When 
histological re-assessment of all samples was carried 
out, two specimens were re-classified as a poorly dif-
ferentiated thyroid carcinoma and one as a follicular 
variant of papillary thyroid cancer. Nine samples, 
among them seven carcinomas and two adenomas, 
were considered as oxyphilic tumours. 
Total RNA was extracted by RNEasy columns 
(QIAGEN). Samples were analysed by oligonucleo-
tide microarray HG-U133 Plus 2.0 according to the 
manufacturer ’s protocol (Affymetrix). The detailed 
methods are given in a parallel manuscript describing 
supervised analysis of the dataset (Pfeifer et al., sub-
mitted, [10]). The dataset was pre-processed with the 
RMA and GC-RMA methods, routine R/Bioconductor 
packages were applied. Principal Component Analysis 
(PCA) was applied as a main method of unsupervised 
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analysis. The dataset for this analysis was centered, no 
scaling was applied. We also used our own procedure 
of unsupervised gene selection based on Singular Value 
Decomposition of the dataset [11]. The results of unsu-
pervised analysis are so called Principal Components 
which could be visualised on X-Y plots, showing two 
principal components on each plot. Samples might be 
coloured according to the class membership, but this 
step is done after the procedure was carried out. The 
lists of genes were analysed in regard of their Gene 
Ontology content and hierarchical clustering based 
on the lists was presented. The MSigDB database (Mo-
lecular Signatures Database, Broad Institute, MIT) was 
also used to analyse the biological meaning of selected 
gene lists. For each mode, an analysis of significant 
gene sets, as defined by MSigDB repository and with 
the use of GSEA algorithm was carried out. We also 
performed the analysis of an independent collection of 
normal human tissues, as provided by GNF Institute 
(Genomics Institute of Novartis Research Foundation). 
This was done by clustering of a selected subset of GNF 
data (genes for each mode), and in parallel displaying 
the same clustering for our samples. 
Results
Unsupervised analysis of the full dataset
The first step was to apply Principal Component 
Analysis to all the samples obtained in the study. 
Principal Components #1 and #2 are shown on Fig. 
1A. It is evident that certain samples (mainly carci-
nomas, but also three adenomas) are clear outliers in 
gene expression profile (they have clearly different 
profile to the majority of samples in the analysed 
group). Some of these effects might be influenced 
by the biological differences in these samples, but 
probably they are partially related to the technical 
issues (e.g. the extent of RNA degradation). When 
the same analysis was repeated after exclusion of 
11 outlier samples (Fig. 1B), the clear pattern of dif-
ferences between ‘‘normal’’ thyroid tissue (sample 
from the lobe contralateral to the tumour, depicted 
in red) and thyroid adenomas as well as carcinomas 
(depicted in green and blue) was seen.
First and third Principal Components discriminate 
between carcinomas and adenomas
In the next step, two components which best discrimi-
nated between FTC and FTA, i.e. PC#1 and PC#3, 
were used together to provide unsupervised insight 
into differences between both groups (Fig. 2). Similarly 
to the previous observation, there was a trend towards 
differences in gene expression profile of follicular car-
cinomas (high values of PC#1, low of PC#3) and fol-
licular adenomas (low values of PC#1, high of PC#3). 
When the artificial boundary between both clusters 
was arbitrarily drawn (black line), still the significant 
number of samples were misclassified. In the case of 
the adenoma cluster, at least four carcinomas were 
dispersed within, with one additional lying close to 
the group boundary. Within the cluster of carcinomas, 
at least three adenomas were indistinguishable in an 
unsupervised manner, with additional three within the 
‘grey zone’. With the assumption of the boundary set 
by us, the unsupervised classification was concordant 
with the class membership in 76% of samples in the ‘left’ 
cluster dominated by carcinomas and in 79% of ‘right’ 
Figure 1. Unsupervised analysis of the whole dataset (A) and 
after exclusion of 11 outlier samples (B). First two principal 
components are presented (PC#1 on X axis and PC#2 on Y axis). 
Normal thyroid samples (red dots), follicular thyroid adenomas 
(FTA, green) and follicular carcinomas (FTC, blue) appear in three 
overlapping clusters
Rycina 1. Nienadzorowana analiza całego zbioru danych (A) oraz 
zbioru danych po wyłączeniu 11 próbek odstających (B). Pierwsze 
dwie główne składowe przedstawiono na wykresie (składową 1 — 
PC#1 na osi X, składową 2 — PC#2 na osi Y). Próbki pochodzące 
z utkania tarczycy niezmienionej nowotworowo zaznaczono 
na czerwono, gruczolaki pęcherzykowe tarczycy na zielono, a 
raki pęcherzykowe tarczycy na niebiesko. Wyraźne jest znaczne 
nakładanie się tych trzech grup badanych
A
B
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cluster samples, dominated by adenomas. These rela-
tively high estimates confirm the significant genomic 
differences between two classes, simultaneously point-
ing out the outlier samples. 
Unsupervised analysis of all adenomas  
and carcinomas in the context of tumour histology
In the third step, we used the full set of 52 carcinomas 
and adenomas, with no exclusions (Fig. 3). Again, we 
might notice the difference between two populations 
when PC#1 and PC#3 are considered, although less 
visible than in the previous figure. When the informa-
tion about histological parameters of samples was used 
to colour the points, it became evident that some of 
the outlier samples showed oncocytic features of the 
tumour, while the majority of non-oncocytic tumours 
cluster were within the main group of tumours. Also, 
two poorly differentiated tumours showed certain 
features of similarity to the group of outliers, although 
not evident enough to be identified in an unsupervised 
manner. Of interest, the one follicular variant of PTC 
which appeared in the analysed group did not differ 
strongly from the remaining follicular tumours in the 
context of PC#1 and PC3# variability. 
The biological meaning of observed differences
We carried out an extensive analysis of the biological 
character of genes correlated to the first six Principal 
Components. When genes, correlated to the first PC, 
were used to cluster carcinoma and adenoma samples, 
they appeared in two clusters: one with larger homog-
enous expression of subset of genes, relatively enriched 
in adenomas, and the other with various degrees of 
Figure 2. Unsupervised analysis of adenoma (FTA, red) and 
carcinoma samples (FTC, blue) by PC#1 and PC#3, outlier 
samples were excluded. Potential boundary between two clusters 
is marked by black line, with the number of outliers provided
Rycina 2. Analiza nienadzorowana zbioru gruczolaków 
pęcherzykowych (FTA, zaznaczone na czerwono) oraz raków 
pęcherzykowych (FTC, zaznaczone na niebiesko). Wykorzystano 
dwie główne składowe, składową pierwszą (PC#1) i trzecią 
(PC#3), wyłączono próbki znacznie odstające. Zaznaczono 
możliwą granicę między dwoma klastrami (czarna ciągła linia), 
przedstawiono także liczbę próbek nie poddających się takiej próbie 
klasyfikacji
Figure 3. Analysis of the core set of samples (without exclusion of outliers) by Principal Component Analysis. PC#1 and PC#3 are 
shown. A. It is apparent that neither PC#1 nor PC#3 provides the differentiation between carcinomas and adenomas; it is necessary to 
use the information from both principal components. B. When the same plot was coloured according to the oxyphilic features of tumours 
(red), some of these tumours appear to be the outliers with very low values of PC#1. Two poorly differentiated carcinomas (black) are 
also showing the relatively low values of PC#1. One sample inadvertently used in the study (follicular variant of papillary thyroid 
carcinoma, fvPTC, green) is not significantly outlying from the remaining follicular tumours
Rycina 3. Analiza głównego zbioru próbek (tylko raki i gruczolaki pęcherzykowe, ale bez wyłączania próbek odstających) za pomocą 
analizy głównych składowych. Przedstawiono dwie główne składowe, składową pierwszą (PC#1) i trzecią (PC#3). A. Wyraźnie widać że 
ani składowa pierwsza ani trzecia samodzielnie nie pozwalają na rozróżnienie obu grup, trzeba wykorzystać obie składowe równocześnie. 
B. Kiedy wykorzystano informacje dot. badań histopatologicznych próbki i zaznaczono te guzy w których stwierdzano cechy oksyfilności 
(czerwone); część z tych guzów ma charakter silnie odstający, z niskimi wartościami PC#1. Dwa niskozróżnicowane raki tarczycy 
(czarne) również wykazują względnie niskie wartości PC#1 w porównaniu z resztą próbek. Jedna z trzech próbek reklasyfikowanych 
(rak brodawkowaty wariant pęcherzykowy) wykazuje profil względnie zbliżony do pozostałych guzów
A B
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down-regulation of these genes and heterogeneous 
up-regulation of smaller cluster of transcripts, see Fig. 
4A; the second cluster shows the relative enrichment 
of carcinomas. One may note that the clustering by the 
major source of variability provided by the first Princi-
pal Component is related neither to the tumour batch 
nor to the hybridisation batch, thus, the analysed vari-
ability does not arise from the technical factors (Fig. 4A). 
When the analysed clustering was shown parallel 
to the clustering by the same list of genes (presented 
Figure 4. Clustering of samples and genes by the gene list of transcripts correlated to the first Principal Component (PC#1). A. Clustering 
of the set of follicular carcinomas (FTC, blue) and adenomas (FTA, green). Sample batch and hybridisation batch are provided by colour 
to demonstrate that these two are not behind the observed variability. Left cluster of samples is relatively enriched in adenomas, while 
the right branch of dendrograms contains a large proportion of carcinomas
Rycina 4. Klasteryzacja próbek i genów za pomocą listy transkryptów skorelowanych z pierwszą główną składową (PC#1). A. Klasteryzacja 
zbioru raków (FTC, niebieskie) i gruczolaków pęcherzykowych (FTA, zielone). Seria próbki oraz hybrydyzacji mikromacierzowej są również 
zaznaczone kolorem, nie są one ewidentnie związane z głównymi źródłami zmienności. Lewy klaster dendrogramu zawiera nieco więcej 
gruczolaków, podczas gdy prawa gałąź grupuje więcej raków pęcherzykowych
A
B
333
Endokrynologia Polska 2013; 64 (5)
PR
A
C
E 
O
RY
G
IN
A
LN
E
in the same order) on the collection of healthy hu-
man tissues (made available by Genomics Institute of 
Novartis Research Foundation, Fig. 4B) it was revealed 
that genes highly up-regulated, mainly in adenomas, 
were the thyroid-specific transcripts, some of them 
up-regulated also in liver (deiodinases). In the oppo-
site, the second cluster of genes, with heterogeneous 
expression in the dendrogram branch enriched in 
carcinomas, contained immunity-related transcripts 
like HLA-DR, DQ genes and may be a genomic indi-
cator of tissue infiltration by lymphocytes and other 
immune system cells. 
In a similar manner, we analysed genomic context 
of the next Principal Components. Immunity-related 
transcripts were identified as those influencing the 
first, third and sixth principal components. First and 
third principal components were similar in their 
genetic content, as they contained the immunity-
related genes and provided the best discrimination 
between carcinomas and adenomas; third PC genes 
were not as apparently thyroid-related as PC#1 
genes. Within the PC#4 we identified a large num-
ber of genes related to mitochondrial function; we 
consider this component as directly related to the 
tumour oxyphilicity features [12]. Within the fifth 
principal component, there were a large number of 
genes related to cell cycle and proliferation. A full 
analysis of the data is provided as a web appendix to 
this article, available online at www.zmnieo.home.pl.
Discussion
In our unsupervised analysis of follicular thyroid tu-
mours, we identified the following sources of variabil-
ity: oncocytic features [12], cell cycle and proliferation 
genes [13], immunity-related transcripts and expression 
of thyroid-specific genes [14]. 
Most of these have been shown previously, except 
immunity-related transcripts. Putting these factors in 
order of importance is not a trivial task, although it 
seems evident that thyroid-specific genes are the larg-
est and strongest factor appearing in our analysis. On 
the other hand, immune response seems to be the most 
multifactorial and complicated variable, influencing to 
a lesser extent at least three principal components of 
the analysis.
In our previous analysis of papillary thyroid cancer 
(PTC) and contralateral normal thyroid tissues, we ap-
plied unsupervised analysis to seek for the potential 
sources of variability [15]. We found that the difference 
between PTC and normal thyroid was prominent and 
could be seen as the major source of variance. We also 
noted that immunity-related transcripts were the other 
strong factor influencing the overall profile of gene ex-
pression. We hypothesised that the variable expression 
of these transcripts was both endogenous (coming from 
expression in thyreocytes) and exogenous (transcripts 
from the immune cells infiltrating the tumour). 
In the study we found that at least in certain fol-
licular tumours it is possible to apply unsupervised 
analysis and discriminate between FTC and FTA. Ap-
prox. 80% of tumours could easily be discriminated 
between clusters, while the remaining samples lie in 
between and could not be distinguished. It is certainly 
difficult to judge whether histopathological diagnosis 
of the analysed samples is accurate, and whether some 
of the follicular adenomas are in fact tumours with gene 
expression profile of cancer, but do not manifest the 
invasive properties. Also the opposite misclassification 
(falsely positive diagnosis of cancer) could influence 
results. Our previous studies on the accuracy of histo-
pathological diagnosis of thyroid cancer [16] indicate 
that the misclassification rate is substantial, even among 
experienced histopathologists. 
There have been a number of genomic studies 
dealing with the classification of follicular thyroid tu-
mours by genomic tests [17–22]. The recent paper by 
Alexander et al. provides a clinically useful tool to dis-
criminate gene expression patterns of thyrocytes even 
in fine-needle aspiration biopsy [23–24]. However, all 
the studies carried out until now do not provide the 
ideal classification accuracy for follicular tumours, 
and they claim a misclassification rate of between 
5% and 30%. Thus, we undertook our study to verify 
the genomic distance between FTC and FTA and test 
whether it is large enough to provide good results 
of molecular classifiers. Our previous analyses [25] 
showed that for papillary thyroid cancer the genomic 
distance is high, and thus the misclassification rate 
might be very low. For follicular neoplasms analysed 
in the present study, we observed significant overlap 
between the two datasets and we estimate that the 
misclassification rate must be between 10% and 20% 
in an unsupervised approach. 
Conclusions
In conclusion, the difference between follicular thy-
roid carcinoma and thyroid adenoma is moderate. 
Approx. 80% of samples could be discriminated in 
unsupervised analysis, while the remaining samples 
constitute the grey zone and could not be discrimi-
nated in that way. At least two principal components 
are necessary to provide such discrimination, con-
firming the multifactorial mechanisms driving the 
invasive potential of follicular carcinomas. Partially 
the expression of thyroid-specific genes and immu-
nity-related transcripts improves the unsupervised 
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classification of follicular tumours. The influence of 
oxyphilic character of some thyroid tumours might 
also be a strong factor appearing as a strong source 
of gene expression variability. 
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